Skip to main content
SpringerLink
Log in

Clinical Applications of [123I]FP-CIT SPECT Imaging

  • Chapter
  • First Online:
PET and SPECT in Neurology

Abstract

Dopamine transporter (DAT) imaging with [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ([123I]FP-CIT) SPECT is commonly used in routine clinical studies to exclude or detect a loss of striatal DATs in individual patients with a movement disorder or dementia. In this chapter, we describe the clinical applications of [123I]FP-CIT SPECT imaging. To facilitate the interpretation of [123I]FP-CIT SPECT images, we first describe the results of [123I]FP-CIT SPECT studies in healthy controls. Thereafter, we describe the typical findings when applying this technique in movement disorders and dementia characterised by loss of striatal DATs (e.g. Parkinson’s disease and dementia with Lewy bodies). We will also describe the possibilities to analyse [123I]FP-CIT SPECT scans in the setting of routine clinical practice. Finally, we briefly discuss the characterisation of extrastriatal [123I]FP-CIT binding and its potential role in future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abi-Dargham A, Gandelman MS, DeErausquin GA et al (1996) SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 37:1129–1133

    CAS  PubMed  Google Scholar 

  • Aguirregomozcorta M, Stamelou M, Antonini A, et al (2013) Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. J Neurol 260:1132–1135

    Google Scholar 

  • Allard P, Marcusson JO (1989) Age-correlated loss of dopamine uptake sites with [3H]GBR-12935 in human putamen. Neurobiol Aging 10:661–664

    CAS  PubMed  Google Scholar 

  • Andringa G, Drukarch B, Bol JG et al (2005) Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson’s disease. Neuroimage 26:1150–1158

    PubMed  Google Scholar 

  • Antonini A, Benti R, De Notaris R et al (2003) 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 24:149–150

    CAS  PubMed  Google Scholar 

  • Antonini A, Vitale C, Barone P et al (2012) The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Relat Disord 18:775–780

    CAS  PubMed  Google Scholar 

  • Auning E, Rongve A, Fladby T et al (2011) Early and presenting symptoms of dementia with lewy bodies. Dement Geriatr Cogn Disord 32:202–208

    PubMed  Google Scholar 

  • Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N (2011) SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging 38:764–773

    PubMed  Google Scholar 

  • Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ (2010) Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry 81:1223–1228

    PubMed  Google Scholar 

  • Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510

    CAS  PubMed  Google Scholar 

  • Benítez-Rivero S, Marín-Oyaga VA et al (2013) Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson’s disease. J Neurol Neurosurg Psychiatry 84:122–129

    Google Scholar 

  • Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, Wolters EC (2001) Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol 50:34–41

    CAS  PubMed  Google Scholar 

  • Best SE, Sarrel PM, Malison RT et al (2005) Striatal dopamine transporter availability with [123I]β-CIT SPECT is unrelated to gender or menstrual cycle. Psychopharmacology 183:181–189

    CAS  PubMed  Google Scholar 

  • Booij J, Tissingh G, Boer GJ et al (1997a) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:133–140

    CAS  PubMed Central  PubMed  Google Scholar 

  • Booij J, Andringa G, Rijks LJ et al (1997b) [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 27:183–190

    CAS  PubMed  Google Scholar 

  • Booij J, Speelman JD, Horstink MW, Wolters EC (2001) The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28:266–272

    CAS  PubMed  Google Scholar 

  • Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL (2007) Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 48:359–366

    CAS  PubMed  Google Scholar 

  • Booij J, Kemp P (2008) Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 35:424–438

    CAS  PubMed  Google Scholar 

  • Booij J, van Amelsvoort T, Boot E (2010) Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: potential role for dopamine transporter imaging. Am J Med Genet A 152A:2937–2938

    PubMed  Google Scholar 

  • Booij J, van Wieringen JP, van de Giessen EM, Knol RJJ, and Finnema SJ (2014) PET and SPECT imaging of the central dopamine system in humans. In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, eds. PET and SPECT of Neurobiological Systems. Springer 229–248

    Google Scholar 

  • Bovi T, Antonini A, Ottaviani S et al (2010) The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J Neurol 257:1882–1889

    PubMed  Google Scholar 

  • Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F (2007) The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging 34:1240–1253

    PubMed  Google Scholar 

  • Catafau AM, Tolosa E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group (2004) Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19:1175–1182

    PubMed  Google Scholar 

  • Ceravolo R, Volterrani D, Gambaccini G et al (2004) Presynaptic nigro-striatal function in a group of Alzheimer’s disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm 111:1065–1073

    CAS  PubMed  Google Scholar 

  • Cilia R, Rossi C, Frosini D, Volterrani D et al (2011) Dopamine transporter SPECT imaging in corticobasal syndrome. PLoS One 6:e18301

    CAS  PubMed Central  PubMed  Google Scholar 

  • Colloby SJ, McParland S, O’Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain 135:2798–2808

    PubMed  Google Scholar 

  • Costa A, Riedel M, Müller U, Möller HJ, Ettinger U (2011) Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies. Synapse 65:998–1005

    CAS  PubMed  Google Scholar 

  • Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P (2011) The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134:3146–3166

    PubMed  Google Scholar 

  • De Keyser JD, Ebinger G, Vauquelin G (1990) Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 27:157–161

    PubMed  Google Scholar 

  • Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P (2010) Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease. Eur J Nucl Med Mol Imaging 37:556–564

    PubMed  Google Scholar 

  • Dickson DW, Bergeron C, Chin SS et al (2002) Neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946

    CAS  PubMed  Google Scholar 

  • Dickson JC, Tossici-Bolt L, Sera T et al (2012) Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging 39:188–197

    PubMed  Google Scholar 

  • El Fakhri G, Habert MO, Maksud P, Kas A, Malek Z, Kijewski MF, Lacomblez L (2006) Quantitative simultaneous (99 m)Tc-ECD/123I-FP-CIT SPECT in Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 33:87–92

    PubMed  Google Scholar 

  • Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL (2009) Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging 36:454–462

    CAS  PubMed  Google Scholar 

  • Eusebio A, Azulay JP, Ceccaldi M, Girard N, Mundler O, Guedj E (2012) Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. Eur J Nucl Med Mol Imaging 39:1778–1783

    CAS  PubMed  Google Scholar 

  • Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(Suppl 4):IV37–IV42

    PubMed  Google Scholar 

  • Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301

    PubMed  Google Scholar 

  • Filippi L, Manni C, Pierantozzi M et al (2005) 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 26:421–426

    CAS  PubMed  Google Scholar 

  • Gerschlager W, Bencsits G, Pirker W et al (2002) [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord 17:518–523

    PubMed  Google Scholar 

  • Goebel G, Seppi K, Donnemiller E et al (2011) A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. Eur J Nucl Med Mol Imaging 38:702–710

    PubMed  Google Scholar 

  • González AM, Berciano J, Figols J, Pazos A, Pascual J (2000) Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration. Brain Res 852:228–232

    PubMed  Google Scholar 

  • Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA (1999) Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 40:1091–1097

    CAS  PubMed  Google Scholar 

  • Hall DA, Jennings D, Seibyl J, Tassone F, Marek K (2010) FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients. Parkinsonism Relat Disord 16:608–611

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hesse S, Meyer PM, Strecker K et al (2009) Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging 36:428–435

    CAS  PubMed  Google Scholar 

  • Iranzo A, Lomeña F, Stockner H et al (2010) Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 9:1070–1077

    CAS  PubMed  Google Scholar 

  • Isaias IU, Benti R, Cilia R et al (2007) [123I]FP-CIT striatal binding in early Parkinson’s disease patients with tremor vs. akinetic-rigid onset. Neuroreport 18:1499–1502

    PubMed  Google Scholar 

  • Ishikawa T, Dhawan V, Kazumata K et al (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123-bCIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 37:1760–1765

    CAS  PubMed  Google Scholar 

  • Jacobsen LK, Staley JK, Zoghbi SS et al (2000) Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 157:1700–1703

    CAS  PubMed  Google Scholar 

  • Kaufman MJ, Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s-diseased striatum. Synapse 9:43–49

    CAS  PubMed  Google Scholar 

  • Kägi G, Bhatia KP, Tolosa E (2010) The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 81:5–12

    PubMed  Google Scholar 

  • Kas A, Payoux P, Habert MO et al (2007) Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med 48:1459–1467

    PubMed  Google Scholar 

  • Kish SJ, Chang LJ, Mirchandani L (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18:530–536

    CAS  PubMed  Google Scholar 

  • Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 318:876–880

    CAS  PubMed  Google Scholar 

  • Klaffke S, Kuhn AA, Plotkin M, Amthauer H, Harnack D, Felix R, Kupsch A (2006) Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 21:1724–1727

    PubMed  Google Scholar 

  • Knudsen GM, Karlsborg M, Thomsen G et al (2004) Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 31:1631–1638

    CAS  PubMed  Google Scholar 

  • Kolenc M, Popović M, Grmek M, Pirtošek Z, Trošt M (2012) A case of multiple system atrophy with normal dopamine transporter imaging. J Neurol 259:2719–2731

    Google Scholar 

  • Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J (2012) Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med 53:1087–1090

    CAS  PubMed  Google Scholar 

  • Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA (2000) Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27:867–869

    CAS  PubMed  Google Scholar 

  • Lim TT, Ahmed A, Itin I, Gostkowski M, Rudolph J, Cooper S, Fernandez HH (2013) Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease? Int J Neurosci 123:170–174

    Google Scholar 

  • Lin JJ, Chang DC (1997) Tremor caused by ipsilateral chronic subdural hematoma. Case illustration. J Neurosurg 87:474

    CAS  PubMed  Google Scholar 

  • Løkkegaard A, Werdelin LM, Friberg L (2002) Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 29:1623–1629

    PubMed  Google Scholar 

  • McKeith I, O’Brien J, Walker Z et al (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6:305–313

    PubMed  Google Scholar 

  • Marek KL, Seibyl JP, Zoghbi SS et al (1996) [123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46:231–237

    CAS  PubMed  Google Scholar 

  • Marshall V, Grosset D (2003) Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18:1415–1423

    PubMed  Google Scholar 

  • Marshall VL, Reininger CB, Marquardt M et al (2009) Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 24:500–508

    PubMed  Google Scholar 

  • McGeer PL, McGeer EG, Suzuki J (1977) Aging and extrapyramidal function. Arch Neurol 34:33–35

    CAS  PubMed  Google Scholar 

  • Meyer PT, Winz OH, Dafotakis M, Werner CJ, Krohn T, Schäfer WM (2011) Improved visual [123I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. Q J Nucl Med Mol Imaging 55:301–309

    CAS  PubMed  Google Scholar 

  • Morgan S, Kemp P, Booij J et al (2012) Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry 83:1063–1070

    PubMed  Google Scholar 

  • Muñoz E, Iranzo A, Rauek S et al (2011) Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). J Neurol 258:2248–2253

    PubMed  Google Scholar 

  • Neumeyer JL, Wang S, Gao Y et al (1994) N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 37:1558–1561

    CAS  PubMed  Google Scholar 

  • O’Brien JT, Colloby S, Fenwick J et al (2004) Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61:919–925

    PubMed  Google Scholar 

  • O’Brien JT, McKeith IG, Walker Z et al (2009) Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 194:34–39

    PubMed  Google Scholar 

  • O’Sullivan SS, Burn DJ, Holton JL, Lees AJ (2008) Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. Mov Disord 23:2424–2426

    PubMed  Google Scholar 

  • Oyanagi K, Tsuchiya K, Yamazaki M, Keda K (2001) Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. J Neuropathol Exp Neurol 60:393–402

    CAS  PubMed  Google Scholar 

  • Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB (2012) Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 18:225–229

    Google Scholar 

  • Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of Pramipexole vs levodopa Parkinson disease progression. JAMA 287:1653–1661

    Google Scholar 

  • Perju-Dumbrava LD, Kovacs GG, Pirker S, Jellinger K, Hoffmann M, Asenbaum S, Pirker W (2012) Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy. Mov Disord 27:65–71

    PubMed  Google Scholar 

  • Perry E, Court J, Goodchild R et al (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 105:915–933

    CAS  PubMed  Google Scholar 

  • Plotkin M, Amthauer H, Klaffke S et al (2005) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112:677–692

    CAS  PubMed  Google Scholar 

  • Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181

    PubMed  Google Scholar 

  • Ponsen MM, Stoffers D, Wolters EC, Booij J, Berendse HW (2010) Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry 81:396–399

    PubMed  Google Scholar 

  • Radau PE, Linke R, Slomka PJ, Tatsch K (2000) Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 41:220–227

    CAS  PubMed  Google Scholar 

  • Roselli F, Pisciotta NM, Perneczky R et al (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 24:2097–2103

    PubMed  Google Scholar 

  • Roselli F, Pisciotta NM, Pennelli M et al (2010) Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord 25:1853–1859

    PubMed  Google Scholar 

  • Ruberg M, Javoy-Agid F, Hirsch E et al (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18:523–529

    CAS  PubMed  Google Scholar 

  • Scheffel U, Lever JR, Abraham P et al (1997) N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse 25:345–349

    CAS  PubMed  Google Scholar 

  • Scherfler C, Seppi K, Donnemiller E et al (2005) Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson’s disease. Brain 128:1605–1612

    PubMed  Google Scholar 

  • Schneider SA, Edwards MJ, Mir P, Cordivari C, Hooker J, Dickson J, Quinn N, Bhatia KP (2007) Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 22:2210–2215

    PubMed  Google Scholar 

  • Seppi K, Scherfler C, Donnemiller E et al (2006) Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. Arch Neurol 63:1154–1160

    PubMed  Google Scholar 

  • Sixel-Döring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C (2011) The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 258:2147–2154

    PubMed  Google Scholar 

  • Spiegel J, Hellwig D, Samnick S et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Transm 114:331–335

    CAS  PubMed  Google Scholar 

  • Stiasny-Kolster K, Doerr Y, Möller JC et al (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137

    CAS  PubMed  Google Scholar 

  • Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW (2005) Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson’s disease. Eur J Nucl Med Mol Imaging 32:689–695

    PubMed  Google Scholar 

  • Tatsch K (2012) Standardisation and harmonisation boost the credibility of nuclear medicine procedures. Eur J Nucl Med Mol Imaging 39:186–187

    PubMed  Google Scholar 

  • Tatsch K, Poepperl G (2012) Quantitative approaches to dopaminergic brain imaging. Q J Nucl Med Mol Imaging 56:27–38

    CAS  PubMed  Google Scholar 

  • Tinazzi M, Antonini A, Bovi T et al (2009) Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 256:910–915

    PubMed  Google Scholar 

  • Tissingh G, Booij J, Bergmans P et al (1998) Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med 39:1143–1148

    CAS  PubMed  Google Scholar 

  • van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J (2009) Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med 50:45–52

    PubMed  Google Scholar 

  • van de Giessen EV, Hesse S, Caan MW et al (2013) No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. Neuroimage 64:61–67

    PubMed  Google Scholar 

  • van Dyck CH, Seibyl JP, Malison RT et al (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10:36–43

    PubMed  Google Scholar 

  • van Dyck CH, Malison RT, Jacobsen LK et al (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46:745–751

    PubMed  Google Scholar 

  • Van Laere K, Casteels C, De Ceuninck L et al (2006) Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med 47:384–392

    PubMed  Google Scholar 

  • Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1023–1032

    CAS  PubMed  Google Scholar 

  • Varrone A, Dickson JC, Tossici-Bolt L et al (2013) European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 40:213–227

    Google Scholar 

  • Walker Z, Costa DC, Walker RW et al (2002) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134–140

    CAS  PubMed Central  PubMed  Google Scholar 

  • Walker Z, Costa DC, Walker RW et al (2004) Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62:1568–1572

    CAS  PubMed  Google Scholar 

  • Walker Z, Jaros E, Walker RW et al (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78:1176–1181

    PubMed Central  PubMed  Google Scholar 

  • Warren NM, Piggott MA, Greally E, Lake M, Lees AJ, Burn DJ (2007) Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. Mov Disord 22:1594–1600

    PubMed  Google Scholar 

  • Zijlmans J, Booij J, Valk J, Lees A, Horstink M (2002) Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway. Mov Disord 17:1086–1088

    PubMed  Google Scholar 

  • Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ, Costa D (2007) [123I]FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Mov Disord 22:1278–1285

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, F2N, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands

    Jan Booij

  2. Department of Neurology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands

    Marina A. J. Tijssen

  3. Department of Neurology, VU University Medical Center Amsterdam, 7057, Amsterdam, 1007 MB, The Netherlands

    Henk W. Berendse

Authors
  1. Jan Booij
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marina A. J. Tijssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henk W. Berendse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Booij .

Editor information

Editors and Affiliations

  1. Dept. of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    Rudi A.J.O. Dierckx

  2. Faculty of Electrical Engineering and Information Technology, University of Applied Sciences Offenburg, Offenburg, Germany

    Andreas Otte

  3. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Erik F.J. de Vries

  4. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Aren van Waarde

  5. Neurology, University Medical Center Groningen, Groningen, The Netherlands

    Klaus L. Leenders

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Booij, J., Tijssen, M.A.J., Berendse, H.W. (2014). Clinical Applications of [123I]FP-CIT SPECT Imaging. In: Dierckx, R., Otte, A., de Vries, E., van Waarde, A., Leenders, K. (eds) PET and SPECT in Neurology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54307-4_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54307-4_33

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54306-7

  • Online ISBN: 978-3-642-54307-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation